Evaluation of death pathway genes FAS and FASL polymorphisms in chronic HBV infection

International Journal of Immunogenetics

Volumn 40, Issue 6, 2013, Pages 482-487

  Zamani, A G ^a   Barlas, I O ^b   Durakbasi Dursun, G ^a   Ural, O ^c   Erdal, E ^b   Yildirim, M S ^a  

^a NECMETTIN ERBAKAN UNIVERSITY   (Turkey)

^b MERSIN UNIVERSITY   (Turkey)

^c SELCUK UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; FAS LIGAND;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HEPATITIS DELTA VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; VIRAL CLEARANCE;

HEPATITIS B VIRUS;

ADULT; AGED; ALLELES; ANTIGENS, CD95; CASE-CONTROL STUDIES; FAS LIGAND PROTEIN; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HOST-PATHOGEN INTERACTIONS; HUMANS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84887619924     PISSN: 17443121     EISSN: 1744313X     Source Type: Journal    
DOI: 10.1111/iji.12056     Document Type: Article

References (27)

1. Agarwal, K., Czaja, A.J. & Donaldson, P.T. (2007) A functional Fas promoter polymorphism is associated with a severe phenotype in type 1 autoimmune hepatitis characterized by early development of cirrhosis. Tissue Antigens, 69, 227.
2. Aguilar-Reina, J., Ruiz-Ferrer, M., Pizarro, M.A. & Antiñolo, G. (2005) The -670A > G polymorphism in the promoter region of the FAS gene is associated with necrosis in periportal areas in patients with chronic hepatitis C. Journal of Viral Hepatitis, 12, 568.
3. Bertoletti, A. & Gehring, A.J. (2006) The immune response during hepatitis B virus infection. Journal of General Virology, 87, 1439.
4. Bortolami, M., Kotsafti, A., Cardin, R. & Farinati, F. (2008) Fas/FasL system, IL-1 beta expression and apoptosis in chronic HBV and HCV liver disease. Journal of Viral Hepatitis, 15, 515.
5. Fuks, A., Parton, L.A., Polavarapu, S., Netta, D., Strassberg, S., Godi, I. & Hsu, C.D. (2005) Polymorphism of Fas and Fas ligand in preterm premature rupture of membranes in singleton pregnancies. American Journal of Obstetrics and Gynecology, 193, 1132.
6. Griffith, T.S., Brunner, T., Fletcher, S.M., Green, D.R. & Ferguson, T.A. (1995) Fas ligand-induced apoptosis as a mechanism of immune privilege. Science, 270, 1189.
7. Huang, Q.R., Morris, D. & Manolios, N. (1997) Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. Molecular Immunology, 34, 577.
8. Huang, Q.R., Danis, V., Lassere, M., Edmonds, J. & Manolios, N. (1999) Evaluation of a new Apo-1/Fas promoter polymorphism in rheumatoid arthritis and systemic lupus erythematosus patients. Rheumatology (Oxford), 38, 645.
9. Jung, Y.J., Kim, Y.J., Kim, L.H., Lee, S.O., Park, B.L., Shin, H.D. & Lee, H.S. (2007) Putative association of Fas and FasL gene polymorphisms with clinical outcomes of hepatitis B virus infection. Intervirology, 50, 369.
10. Kanemitsu, S., Ihara, K., Saifddin, A., Otsuka, T., Takeuchi, T., Nagayama, J., Kuwano, M. & Hara, T. (2002) A functional polymorphism in fas (CD95/APO-1) gene promoter associated with systemic lupus erythematosus. Journal of Rheumatology, 296, 1183.
11. Kondo, T., Suda, T., Fukuyama, H., Adachi, M. & Nagata, S. (1997) Essential roles of the Fas ligand in the development of hepatitis. Nature Medicine, 3, 409.
12. Krammer, P.H., Behrmann, I., Daniel, P., Dhein, J. & Debatin, K.M. (1994) Regulation of apoptosis in the immune system. Current Opinion in Immunology, 6, 279.
13. Lee, S.H., Lee, J.Y., Park, W.S., Kim, S.Y., Jang, J.J. & Yoo, N.J. (1999) Transitional cell carcinoma expresses high levels of Fas ligand in vivo. BJU International, 83, 698.
14. Li, C., Larson, D., Zhang, Z., Liu, Z., Strom, S.S., Gershenwald, J.E., et al. (2006a) Polymorphisms of the FAS and FAS ligand genes associated with risk of cutaneous malignant melanoma. Pharmacogenetics and Genomics, 16, 253.
15. Li, C., Wu, W., Liu, J., Qian, L., Li, A., Yang, K., Wei, Q., Zhou, J. & Zhang, Z. (2006b) Functional polymorphisms in the promoter regions of the FAS and FAS ligand genes and risk of bladder cancer in south China: a case-control analysis. Pharmacogenetics and Genomics, 16, 245.
16. Miller, S.A., Dykes, D.D. & Polesky, H.F. (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Research, 16, 1215.
17. Natori, S., Rust, C., Stadheim, L.M., Srinivasan, A., Burgart, L.J. & Gores, G.J. (2001) Hepatocyte apoptosis is a pathologic feature of human alcoholic hepatitis. Journal of Hepatology, 34, 248.
18. Ogasawara, J., Watanabe-Fukunaga, R., Adachi, M., Matsuzawa, A., Kasugai, T., Kitamura, Y., Itoh, N., Suda, T. & Nagata, S. (1993) Lethal effect of the anti-Fas antibody in mice. Nature, 364, 806.
19. Park, S.H., Choi, J.E., Kim, E.J., Jang, J.S., Lee, W.K., Cha, S.I., et al. (2006) Polymorphisms in the FAS and FASL genes and risk of lung cancer in a Korean population. Lung Cancer, 54, 303.
20. Pinkoski, M.J., Brunner, T., Green, D.R. & Lin, T. (2000) Fas and Fas ligand in gut and liver. American Journal of Physiology. Gastrointestinal and Liver Physiology, 278, G354.
21. Ruiz-Ferrer, M., Antiñolo, G. & Aguilar-Reina, J. (2007) Analysis of the -844C > T polymorphism in the promoter region of FASL gene in a cohort of Spanish HCV patients. Journal of Viral Hepatitis, 14, 293.
22. Shimonishi, T., Isse, K., Shibata, F., Aburatani, I., Tsuneyama, K., Sabit, H., Harada, K., Miyazaki, K. & Nakanuma, Y. (2000) Up-regulation of fas ligand at early stages and down-regulation of Fas at progressed stages of intrahepatic cholangiocarcinoma reflect evasion from immune surveillance. Hepatology, 32, 761.
23. Sibley, K., Rollinson, S., Allan, J.M., Smith, A.G., Law, G.R., Roddam, P.L., Skibola, C.F., Smith, M.T. & Morgan, G.J. (2003) Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia. Cancer Research, 63, 4327.
24. Stuck, B.J., Pani, M.A., Besrour, F., Segni, M., Krause, M., Usadel, K.H. & Badenhoop, K. (2003) Fas ligand gene polymorphisms are not associated with Hashimoto's thyroiditis and Graves' disease. Human Immunology, 64, 285.
25. Sun, T., Miao, X., Zhang, X., Tan, W., Xiong, P. & Lin, D. (2004) Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. Journal of the National Cancer Institute 96, 1030.
26. Wu, J., Metz, C., Xu, X., Abe, R., Gibson, A.W., Edberg, J.C., Cooke, J., Xie, F., Cooper, G.S. & Kimberly, R.P. (2003) A novel polymorphic CAAT/enhancer-binding protein beta element in the FasL gene promoter alters Fas ligand expression: a candidate background gene in African American systemic lupus erythematosus patients. Journal of Immunology, 170, 132.
27. Zhang, X., Miao, X., Sun, T., Tan, W., Qu, S., Xiong, P., Zhou, Y. & Lin, D. (2005) Functional polymorphisms in cell death pathway genes FAS and FASL contribute to risk of lung cancer. Journal of Medical Genetics, 42, 479.